AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
Item8.01. Other Events.
On April28, 2017, members of the management team of Amicus
Therapeutics,Inc. (the Company) will present posters related to
its SD-101 program at the 76th Annual Meeting of the Society for
Investigative Dermatology in Portland, Oregon. A copy of these
posters is attached hereto as Exhibit99.1.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits: The ExhibitIndex annexed hereto is incorporated
herein by reference.
|
Exhibit No. |
|
Description |
|
99.1 |
Posters dated April28, 2017 titled Investigation of the |
About AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency. AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Recent Trading Information
AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) closed its last trading session down -0.16 at 7.66 with 1,217,181 shares trading hands.
